Rallybio (RLYB)
(Real Time Quote from BATS)
$1.14 USD
+0.04 (3.64%)
Updated Oct 4, 2024 10:22 AM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Rallybio Corporation (RLYB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.67 | $15.00 | $6.00 | 779.09% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Rallybio Corporation comes to $9.67. The forecasts range from a low of $6.00 to a high of $15.00. The average price target represents an increase of 779.09% from the last closing price of $1.10.
Analyst Price Targets (3 )
Broker Rating
Rallybio Corporation currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/26/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
8/12/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/13/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 5 |
Average Target Price | $9.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | -0.36 |
RLYB FAQs
Rallybio Corporation (RLYB) currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Rallybio Corporation (RLYB) is $9.67. The current on short-term price targets is based on 3 reports.
The forecasts for Rallybio Corporation (RLYB) range from a low of $6 to a high of $15. The average price target represents a increase of $779.09 from the last closing price of $1.10.
The current UPSIDE for Rallybio Corporation (RLYB) is 779.09%
Based on short-term price targets offered by three analysts, the average price target for Rallybio Corporation comes to $9.67. The forecasts range from a low of $6.00 to a high of $15.00. The average price target represents an increase of 779.09% from the last closing price of $1.10.